4 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 4 |
| Phase 1 | 1 | Unknown 1 |
Follow Muscle Invasive Bladder Cancer: new trials by email Literature Review of Muscle Invasive Bladder Cancer trials Research Report on Muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
| A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer APL-1202 in combination with tislelizumab, Tislelizumab alone - Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 79 | 2021-12-28 | 2022-02-22 |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma Tislelizumab, Nab paclitaxel - Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 48 | 2020-07-11 | 2022-11-30 |
| Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer pegylated liposomal doxorubicin (PLD), PD-1 - Muscle Invasive Bladder Cancer | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 60 | 2019-09-17 | 2019-09-26 |
Carcinoma, Transitional Cell (1)
Carcinoma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
tislelizumab (2) · RC48 antibody (1) · Taxes (1) · disitamab vedotin (1) · liposomal doxorubicin (1) · toripalimab (1)
Tianjin Medical University Second Hospital (2) · Jiangsu Yahong Meditech Co., Ltd aka Asieris (1) · RenJi Hospital (1)
China (4) · United States (1)
Haige Chen (1) · Hailong Hu, MD,PhD (1)